Results 101 to 110 of about 88,087 (318)
Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS
Clinical Pharmacology &Therapeutics, EarlyView.Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Thiopurines such as 6‐mercaptopurine (6MP) are essential in ALL maintenance therapy. However, dose‐limiting toxicities can significantly disrupt treatment. While genetic variants in TPMT and NUDT15 are known to affect thiopurine response, many patients with normal function ...
Carlotta Bidoli +5 more
wiley +1 more source
Clinical Pharmacology & Therapeutics: Past, Present, and Future. [PDF]
, 2017 Clinical Pharmacology & Therapeutics (CPT), the definitive and timely source for advances in human therapeutics, transcends the drug discovery, development, regulation, and utilization continuum to catalyze, evolve, and disseminate discipline ...
Terzic, Andre, Waldman, Scott A.
core +2 more sources
Pharmacogenetics of Anticoagulants [PDF]
Human Genomics and Proteomics, 2010 Warfarin, acenocoumarol, and phenprocoumon are among the major anticoagulant drugs worldwide. Because of their low therapeutic index and serious adverse reactions (ADRs), their wide use, and their varying kinetics and pharmacogenetic dependence, it is of great importance to explore further possibilities to forecast the dose beyond conventional INR ...
Anders Rane, Jonatan D. Lindh
openaire +3 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Pharmacogenomics enables the personalization of drug therapy by linking genetic variations to differences in drug metabolism, efficacy, and risk of adverse reactions. Genetic polymorphisms within cytochrome P450 (CYP) genes significantly affect enzyme activity, influencing drug plasma levels, responses, and safety.
Alex J. Coulter +4 more
wiley +1 more source
Pharmacogenetics of antidepressant response: An update
Human Genomics, 2009 The past few decades have witnessed much progress in the field of pharmacogenetics. The identification of the genetic background that regulates the antidepressant response has benefited from these advances.
Drago Antonio +2 more
doaj +1 more source
The future of laboratory medicine - A 2014 perspective. [PDF]
, 2015 Predicting the future is a difficult task. Not surprisingly, there are many examples and assumptions that have proved to be wrong. This review surveys the many predictions, beginning in 1887, about the future of laboratory medicine and its sub ...
FORTINA, PAOLO +3 more
core +1 more source
UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta‐Analysis
Clinical Pharmacology &Therapeutics, EarlyView.Sacituzumab govitecan (SG), a humanized antibody‐drug conjugate, enables intra‐tumor delivery of SN‐38, the active metabolite of irinotecan, with the aim of increasing efficacy. SN‐38 is predominantly inactivated by the polymorphically expressed uridine diphosphate glucuronosyltransferase 1A1 (UGT1AA) where reduced activity can lead to toxicity.
Cinzia Dello Russo +4 more
wiley +1 more source
Pharmacogenetics in type 2 diabetes:Influence on response to oral hypoglycemic agents [PDF]
, 2016 Adem Yesuf Dawed, Kaixin Zhou, Ewan Robert Pearson Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Dundee, Scotland, UK Abstract: Type 2 diabetes is one of the leading causes of morbidity ...
Dawed, Adem Yesuf +2 more
core +4 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N‐acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as “slow acetylators”) are predicted to have increased plasma hydralazine concentrations compared with ...
Michael T. Eadon +18 more
wiley +1 more source
Scientific ReportsNon-alcoholic steatohepatitis (NASH) is a major health problem leading to liver fibrosis and hepatocellular carcinoma, among other diseases, and for which there is still no approved drug treatment. Previous studies in animal models and in LX-2 cells have
Sara Redenšek Trampuž +3 more
doaj +1 more source